DOXORUBICIN HYDROCHLORIDE, LIPOSOMAL, PACLITAXEL, DOXORUBICIN HYDROCHLORIDE, LIPOSOMAL, TOPOTECAN, AZD5335, MIRVETUXIMAB SORAVTANSINE
D8991C00001
Phase 3 small_molecule active
Quick answer
DOXORUBICIN HYDROCHLORIDE, LIPOSOMAL, PACLITAXEL, DOXORUBICIN HYDROCHLORIDE, LIPOSOMAL, TOPOTECAN, AZD5335, MIRVETUXIMAB SORAVTANSINE for Advanced Platinum-resistant Epithelial Ovarian Cancer is a Phase 3 program (small_molecule) at AstraZeneca AB with 1 ClinicalTrials.gov record(s).
Program details
- Company
- AstraZeneca AB
- Indication
- Advanced Platinum-resistant Epithelial Ovarian Cancer
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active